Member Info for comek2

The reduced holding could simply be the adjustment % in light of the enlargement of rms to 1.5 billions shares following p2p acquisition.

Looking at yesterday rns, it would appear rms have been they may have forward sold all the 5 millions masks. Otherwise why NAME and LIMIT the sales to the health, transport and food sectors in a pandemic? If this is the case, then to meet the demand of other sectors and the public, more machines will be purchased.

As expected, next week we will have an update on the machine arrival/installation/operation and at the same time sales figures so far- we know of the 1 million already sold. There should also be a statement of intent to purchase further machines in light of purchase enquires that cannot be fulfilled at the moment, hence the LIMIT to sectors cited above.

If this scenario materialise, and I see no reason why not, then 20p sp will easily be reached within 2/3 trading days because the potential profit for such unique mask in a global pandemic is huge. Because if volume profit from masks should be much more than from tests, yet most tests stocks on hope alone multibagged easily 10, and 1000 times in the case of Ncyt. With RMS it would be real sales starting next month, not hope waiting more than 6 months as eg avct, gdr, odd etc....incidentally I predicted Ncyt reaching £10 when it was hovering around £1, giving sound argument in a post 1/3 of an A4 page. Gla

November 2020

Remote Monitored Systems plc ("RMS" or the "Company")

Pharm 2 Farm Update

The Company notes the fast changing situation regarding possible COVID-19 vaccines. The widely reported and very positive interim trial results of a vaccine developed by Pfizer and BioNTech are hugely encouraging and welcomed by everyone. However, the Directors believe that the roll out of a vaccine will not lessen in the near term demand for its developing viricidal mask product. The Directors also note and welcome the new Scientific Brief released yesterday by the US Centre for Disease Control* expanding on the benefits of masks for both the wearer and the community.

Pharm 2 Farm is focusing on bringing its mask to market as soon as possible. The Directors' expectation is that the mask production line will be delivered and installed in its clean room facility at BioCity Nottingham at the end of this month and that production can begin shortly thereafter.

The Company also notes the announcement from Nottingham Trent University issued this morning and reproduces it in its entirety below.

"Scientists develop facemask which can kill viruses on contact
A new antiviral facemask which uses nanotechnology to kill viruses including COVID-19 and influenza has been designed and developed by a Nottingham Trent University scientist. Instead of the usual three-ply design, the five-ply surgical mask includes an additional antiviral inner layer which incorporates nano-copper created using a patented process developed at the university. The copper, which is embedded into the mask material, has ions that are emitted once in contact with a virus and this then creates an interaction with the virus's genetic material causing it to die and stop reproducing. Because they are spherical, nanoparticles have a large surface area making the approach more effective at killing the virus. The antiviral inner layer ensures additional protection for both the wearer and those in proximity.

The mask has been designed by Nottingham Trent University scientist and nanotechnology expert, Dr Gareth Cave, and is now being commercialised by NTU spin out company Pharm2Farm in Nottingham's BioCity.

The company, which was founded by Dr Cave, uses a patented process to produce and functionalise nanoparticles for a range of human, crop and animal health benefits. Tests showed that the masks, which are Type IIR - meaning they offer the highest level of protection and have a filtration efficiency of 99.98% - were highly effective, at killing more than 90% of the influenza and coronavirus over seven hours, and have been certified to ISO 18184 standards. The masks include a fluid-repellent layer on the outside - to reduce inhalation of droplets of saliva and mucus that carry COVID-19 - the antiviral nanotech layer between two filter layers, and a hypoallergenic breathable innermost layer.
While current conventional surgical masks block the virus, it can remain on or in the

Hooray

France has passed a law of €130 fine on the spot for not wearing mask anywhere in public. Won’t surprised to see other countries following suit. China, Japan, Hong Kong, and South Korea have been successful in getting the pandemic under control because of mask wearing.

If it’d take 2 years for the vaccine to show it’s fully safe, would people rather wear anti-covid mask until then, or risk serious side effects. I know what I’d do for myself and my family.

Remember too Pfizer’s results are interims rather full trials and may experts have raised questions and suggested preventive measures must continue until the whole globe can be vaccinated which they reckon will take years. See the link I provided this morning.

Rms is the only covid stock not affected by Pfizer vaccine. Therefore I’d expect most covid shareholders shaken in the last 2 days to be running into rms. their emotional attachments to covid stocks, not to mention their huge losses, will make them see rms as a safer and the means to recover if not make the profits 2 days ago was still their dream. I sold all my covid stock and topped up into rms.

One examples, among others, where the need for testing and masks wearing must continue:

Prof Azra Ghani, Chair in Infectious Disease Epidemiology, Imperial College London, said:

“These new results represent the first demonstration of substantial efficacy of a vaccine candidate against COVID-19 disease which is very welcome news. It is important to bear in mind that these are early results based on a relatively small number of cases. In addition, the efficacy estimate is based on 7 days of follow-up of participants following the second dose; further data in the coming weeks and months will provide a better picture of longer-term vaccine efficacy.”

https://www.sciencemediacentre.org/expert-reaction-to-pfizer-and-biontech-reporting-interim-results-from-phase-3-covid-19-vaccine-trial/

Are some bb owned by the MMs, of course not directly. Ah the old adage of “the city incestious relationship”.

Is it a coincidence when the markets is volatile particularly with covid19 (more trading) stocks LSE chats shuts down- all other features operate as normal? Surely without the shared information on bbs, people tend to panic and go blindly to buy or sell ie more trading done than normal and at prices MMs dictate.......especially over the 2 last today’s when the vaccine news unsettled covid stocks.

I think people should make a complaint.

I believe shorters shorted rms with the rest of covid19 stocks, not realising rms is different to the test led shares. Therefore I’d expect them to close their positions today. Some of these derampers are shorters panicking as they’ve realised their mistakes....if not they will burn more to oblivion.

Yesterday fall was a blessing in disguise, allowing purchase of rms below 2p. As it’s known MMs always take advantage and Rms was taken down with the rest of covid19 tests stock, yet p2p mask is needed post covid just as they have been pre covid. Irrespective of the vaccine success, P2P mask will be the new standard even for public consumption and home stored as just we do with paracetamol especially during flu season. I foresee employers requesting people with flu to work wearing this mask- flu cost the economy $10s billions yearly. Health services around the world will be using it, not only it’s cost effective but for environmental concerns, 1 mask instead of 4 for 7 hrs as is currently the case. Add to this p2p striving to make it biodegradable. Given this pandemic has caught governments globally with their PPE-pants down, there will be 100s billions needed for stockpiling including for possible future viruses/epidemic/pandemic- recall the sad yet hilarious incident of the US stealing the french plane PPE load off the China airport tarmac, lol. The nanotechnology IP intrinsic value will imo increase as p2p fine tune it for other viruses to cope with/prevent future pandemic- nyct were first with SARS2 (covid19) test because they had previously developed SARA1.

Add to the above P2P agronomy $10s billions market and much more from gyrotec industrial machines markets and rms is no brainer. Boris Johnson has stated renewable energy will be his government priority. The EU has allocated 25% of its €750 billions pandemic budget recovery to green energy.

I used to call nyct “pregnancy with rns” and it sure obliged. I think rms will be more rns pregnant as masks are more numerous and needed more than than test, volume wise. Therefore I’d expected orders rnsSSSSS non stop. I also predicted the £10 share price when around the £1 and within the 6/9 months period and I’m happily surprised it went beyond that, though I was forced to sell well before. Will rms do just 1/10 of that. We shall see. Volume wise, there should be more profit from masks than from tests.

appear not spread, sorry autocorrect lol

FSA15, BRH stopped selling, otherwise Tr1 wouldn’t have been issued.

The reason they spread to have sold is to to fund their 5 mns covid 19 test. Yet they still retain over 25% of rms shares.

....shows strong demand for the shares.

Plus seller done, which is good news. Yet they still retain over 25% and exercised warrants.

I’d suggest BRH sold them to fund the 5 mns test clinical trial. Yesterday Prof Carl on Twitter confirmed documentation for such trial has already been submitted.

9 November 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Share transactions in Remote Monitored Systems plc

Braveheart announces that on 6 November 2020 it exercised a total of 10 million options over ordinary shares in Remote Monitored Systems plc ("RMS") at an exercise price of 0.5p per share ("the RMS Option Shares") and an aggregate cost of £50,000. Braveheart has been advised that application will be made by the directors of RMS for the RMS Option Shares to be admitted to trading on the AIM market and that dealings are expected to commence on or about 13 November 2020.
Braveheart also announces that on 5 and 6 November 2020, it sold a total of 120 million ordinary shares in RMS at a weighted average price of 2.6265p per share, realising gross proceeds of approximately £3.15 million. The net funds receivable by Braveheart are primarily intended to fund the COVID-19 test project, as required and assuming it continues to deliver the results necessary to justify continuing the project, being conducted by Paraytec Limited through to a point where it is ready for commercial launch. Following these sales, Braveheart holds 389,992,405 RMS shares, representing 25.45 per cent. of the voting rights of RMS and following the admission to AIM of the RMS Option Shares will hold 399,992,405 RMS shares, representing 25.94 per cent. of the then enlarged voting rights of RMS.
About RMS
RMS is an operating company whose ordinary shares are admitted to trading on AIM. In the year ended 31 December 2019, RMS incurred a loss before taxation of £711,942 and as at that date had net liabilities of £19,250. As at 30 June 2020 had unaudited net assets of £674,135.

For further information:



Braveheart Investment Group plc
Tel: 01738 587555
Trevor Brown, CEO



Allenby Capital Limited (Nominated Adviser and Joint Broker)
Tel: 020 3328 5656
David Worlidge / James Hornigold



Peterhouse Capital Limited (Joint Broker)
Tel: 020 7469 0936
Heena Karani / Lucy Williams

9 November 2020

Remote Monitored Systems plc ("RMS" or the "Company")

Braveheart Dealings and Exercise of Warrants

The Company announces that on 6 November 2020, it received notification from Braveheart Investment Group plc ("Braveheart") to exercise a total of 10,000,000 warrants over ordinary shares in the Company at an exercise price of 0.5p per warrant. The consideration received by the Company was £50,000.

The 10,000,000 new Ordinary Shares ("Warrant Shares") arising from the exercise of these warrants have been issued, and application has been made for them to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings will commence at 8:00 a.m. on or around 13 November 2020.

The Company has also received notification from Braveheart that on 5 and 6 November 2020, Braveheart sold a total of 120,000,000 ordinary shares in the Company at a weighted average price of 2.6265 pence per share. Following the sale (as well as the issue of the 310,354,815 Consideration Shares issued to Braveheart issued in respect of the acquisition of Pharm2Farm Limited which completed on 5 November 2020), Braveheart holds 389,992,405 RMS shares, representing 25.45 per cent. of the total voting rights in the Company. Following the Admission of the Warrant Shares, Braveheart will hold 399,992,405 RMS shares, representing 25.94 per cent. of the enlarged issued share capital and total voting rights of the Company.

Following Admission, the Company will have 1,542,070,231 ordinary shares of 0.01p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,542,070,231.

The above figure of 1,542,070,231 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.


ENQUIRIES:

Remote Monitored Systems plc

Trevor Brown (Executive Director) +41 7941 55384

Paul Ryan (Non-Executive Chairman) +32 475 754 148



SP Angel Corporate Finance LLP +44 20 3470 0470

Nominated Adviser and joint broker

Stuart Gledhill

Caroline Rowe



Peterhouse Capital Limited +44 20 7469 0930

Joint broker

Lucy Williams

Duncan Vasey

Since the acquisition of p2p is done, why no rns when we’ve had an rns about warrants? This to me suggests that they maybe adding some juicy additional information to excite shareholders about the rational behind such acquisition, eg “p2p is receiving interest about the mask sales from other parties” etc....

RNS Number : 2513E
Remote Monitored Systems PLC
04 November 2020


4 November 2020

Remote Monitored Systems plc ("Remote Monitored Systems", or the "Company")

GM Results and Total Voting Rights


The Company's General Meeting ("GM") was held today at 10.30am. All resolutions were passed and the proxy votes were as follows.

Resolution
For
Against
Discretion to Chairman
Withheld
Total
1
193,464,512
831,097
Nil
75,022
194,370,631
2
193,464,512
831,097
Nil
75,022
194,370,631
3
193,464,512
831,097
Nil
75,022
194,370,631


Acquisition of Pharm2Farm
Shareholders have now approved the Company's acquisition of Pharm2Farm Limited ("P2F"), and accordingly, the acquisition will be completed on 5 November 2020.

As announced on 19 October 2020, the vendors of P2F are Braveheart Investment Group plc (51.72%) ("Braveheart") and Dr. Gareth Cave, the founder of P2F (48.28%) who will receive 310,354,815 and 289,645,185 RMS shares of 0.01 pence each ("Consideration Shares") respectively, equating to an aggregate consideration of approximately £2.3m based on RMS's closing share price of 0.375 pence on 20 August 2020, being the last practicable day prior to the announcement of the acquisition agreement.

On completion of the Acquisition, Braveheart will hold 509,992,405 ordinary shares in the Company, representing 34.08 per cent. of the enlarged issued share capital of the Company. Dr. Gareth Cave will hold 289,645,185 ordinary shares in the Company, representing 19.35 per cent. of the enlarged issued share capital of the Company.

Total Voting Rights
Application has been made for the 600,000,000 Consideration Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings will commence at 8.00a.m. on 5 November 2020.

Following Admission, the Company will have 1,496,627,261 ordinary shares of 0.01p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,496,627,261. The above figure of 1,496,627,261 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

ENQUIRIES:

Remote Monitored Systems plc

https://www.theguardian.com/society/2020/nov/04/six-nhs-staff-contract-covid-after-car-sharing-without-wearing-masks